These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 25936515

  • 1. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M, Uchii M, Myojo K, Kitayama T, Kunori S.
    Eur J Pharmacol; 2015 Aug 15; 761():109-15. PubMed ID: 25936515
    [Abstract] [Full Text] [Related]

  • 2. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
    Uchii M, Kimoto N, Sakai M, Kitayama T, Kunori S.
    Eur J Pharmacol; 2016 Jul 15; 783():56-63. PubMed ID: 27063445
    [Abstract] [Full Text] [Related]

  • 3. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
    Uchii M, Sakai M, Hotta Y, Saeki S, Kimoto N, Hamaguchi A, Kitayama T, Kunori S.
    J Pharmacol Sci; 2017 Nov 15; 135(3):126-130. PubMed ID: 29113790
    [Abstract] [Full Text] [Related]

  • 4. Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats.
    Ikeda J, Kimoto N, Kitayama T, Kunori S.
    J Pharmacol Sci; 2016 Sep 15; 132(1):65-70. PubMed ID: 27666017
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):828-33. PubMed ID: 24342619
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G, Garofolo M, Del Prato S.
    Nutr Metab Cardiovasc Dis; 2016 May 17; 26(5):361-73. PubMed ID: 27105869
    [Abstract] [Full Text] [Related]

  • 10. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
    Gangadharan Komala M, Gross S, Zaky A, Pollock C, Panchapakesan U.
    Nephrology (Carlton); 2016 May 17; 21(5):423-31. PubMed ID: 26375854
    [Abstract] [Full Text] [Related]

  • 11. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
    Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S, Nangaku M.
    Am J Physiol Renal Physiol; 2015 Apr 15; 308(8):F878-87. PubMed ID: 25656369
    [Abstract] [Full Text] [Related]

  • 12. Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats.
    Helmy MM, Mouneir SM.
    Pharmacol Rep; 2019 Dec 15; 71(6):1133-1139. PubMed ID: 31675669
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F.
    Nutr Metab Cardiovasc Dis; 2016 May 15; 26(5):380-6. PubMed ID: 27067162
    [Abstract] [Full Text] [Related]

  • 15. Sodium alginate oligosaccharides attenuate hypertension and associated kidney damage in Dahl salt-sensitive rats fed a high-salt diet.
    Terakado S, Ueno M, Tamura Y, Toda N, Yoshinaga M, Otsuka K, Numabe A, Kawabata Y, Murota I, Sato N, Uehara Y.
    Clin Exp Hypertens; 2012 May 15; 34(2):99-106. PubMed ID: 21967018
    [Abstract] [Full Text] [Related]

  • 16. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.
    Koibuchi N, Hasegawa Y, Katayama T, Toyama K, Uekawa K, Sueta D, Kusaka H, Ma M, Nakagawa T, Lin B, Kim-Mitsuyama S.
    Cardiovasc Diabetol; 2014 Nov 29; 13():157. PubMed ID: 25471116
    [Abstract] [Full Text] [Related]

  • 17. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
    Abouelkheir M, El-Metwally TH.
    Eur J Pharmacol; 2019 Nov 05; 862():172638. PubMed ID: 31491403
    [Abstract] [Full Text] [Related]

  • 18. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
    Jackson EK, Mi Z, Tofovic SP, Gillespie DG.
    Hypertension; 2015 Jan 05; 65(1):238-49. PubMed ID: 25368027
    [Abstract] [Full Text] [Related]

  • 19. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW.
    Clin Pharmacokinet; 2017 Jan 05; 56(1):11-24. PubMed ID: 27282159
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.